Cempra Inc.'s antibiotic solithromycin appears on track for approval by the end of the year as FDA's Antimicrobial Drugs Advisory Committee is scheduled to review the drug at its Nov. 4 meeting.
The panel will discuss Cempra's two new drug applications for oral and intravenous formulations of the drug for treatment of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?